{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:25:09Z","timestamp":1767147909620,"version":"build-2238731810"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jns.2017.05.018","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T05:39:28Z","timestamp":1494567568000},"page":"233-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?"],"prefix":"10.1016","volume":"378","author":[{"given":"Cristina","family":"Scarpazza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Prosperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara R.","family":"Mancinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"De Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Lugaresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Naldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Imberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Gerevini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggero","family":"Capra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2017.05.018_bb0005","first-page":"623","article-title":"Progressive multifocal leukoencephalopathy therapy","volume":"21","author":"Clifford","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jns.2017.05.018_bb0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2017.05.018_bb0015","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/brain\/awr206","article-title":"Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome","volume":"134","author":"Aly","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.jns.2017.05.018_bb0020","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1212\/WNL.0b013e3182768983","article-title":"Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?","volume":"79","author":"Antoniol","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.05.018_bb0025","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1304828","article-title":"Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome","volume":"370","author":"Giacomini","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2017.05.018_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrneurol.2015.248","article-title":"CCR5 blockage for neuroinflammatory diseases-beyond control of HIV","volume":"12","author":"Martin-Blondel","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2017.05.018_bb0035","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jns.2017.05.018_bb0040","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1212\/NXI.0000000000000323","article-title":"Severe early natalizumab-associated PML in MS: effective control of PML-IRIS with Maraviroc","volume":"4","author":"Bseth","year":"2017","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"key":"10.1016\/j.jns.2017.05.018_bb0045","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1212\/NXI.0000000000000325","article-title":"Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS","volume":"4","author":"Hodecker","year":"2017","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"issue":"12","key":"10.1016\/j.jns.2017.05.018_bb0050","doi-asserted-by":"crossref","first-page":"e0168376","DOI":"10.1371\/journal.pone.0168376","article-title":"Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry","volume":"11","author":"Prosperini","year":"2016","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.jns.2017.05.018_bb0055","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.05.018_bb0060","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.05.018_bb0065","series-title":"Evaluation of Chemotherapeutic Agents","first-page":"191","article-title":"The clinical evaluation of chemotherapeutic agents in cancer","author":"Karnofsky","year":"1949"},{"key":"10.1016\/j.jns.2017.05.018_bb0070","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/S2352-3018(14)70027-X","article-title":"Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomized, placebo-controlled trial","volume":"1","author":"Sierra-Madero","year":"2014","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jns.2017.05.018_bb0075","series-title":"32nd Congress of ECTRIMS. Free Communications Session, Power Point presentation","article-title":"To do or not to do? Plasma exchange and steroids in progressive multifocal leukoencephalopathy management","author":"Scarpazza","year":"2016"},{"key":"10.1016\/j.jns.2017.05.018_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.0000000000002330","article-title":"Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay","volume":"86","author":"Gagne Brosseau","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.05.018_bb0085","first-page":"637","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jns.2017.05.018_bb0090","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1212\/WNL.0b013e3182a43e6d","article-title":"In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection","volume":"81","author":"Martin-Blondel","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.05.018_bb0095","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00401-015-1383-6","article-title":"Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome","volume":"129","author":"Martin-Blondel","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jns.2017.05.018_bb0100","first-page":"5447","article-title":"Maraviroc: a review of its use in HIV infection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jns.2017.05.018_bb0105","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1212\/NXI.0000000000000331","article-title":"Maraviroc in PML-IRIS. A separate ball game under HIV infection and natalizumab?","volume":"4","author":"Steiner","year":"2017","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."}],"updated-by":[{"DOI":"10.1016\/j.jns.2017.06.037","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:00:00Z","timestamp":1505433600000}}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17303143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17303143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T19:01:41Z","timestamp":1535828501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17303143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":21,"alternative-id":["S0022510X17303143"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.05.018","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}